PRESS-RELEASE filed Aug 14, 2026 at 07:15 ET
Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missing the consensus estimate of -$0.07. Revenue was negligible at $9K, down from $1.5M a year ago, as the company is pre-commercial launch in the U.S. The filing is dominated by the upcoming U.S. launch of LYTENAVA (wet AMD), with management projecting over $500M in peak annual sales by 2030. However, the severe cash crunch ($11.2M at quarter-end) and subsequent dilutive $51.1M public offering in August 2026 temper the bullish launch narrative, creating a mixed picture where a transformative product launch is offset by immediate financial fragility and shareholder dilution.